This is of clinical relevance, given that biomarkers that are currently used clinically (e.g., Aβ PET) show weaker associations with cognitive decline and brain atrophy, especially at the dementia stage.9,10 However, also within tau-positive patients with AD, large variation in cognition exists. The gene discussed is MAPT; the disease is Brain atrophy.